| Name | Title | Contact Details |
|---|
AmnioLife Corporation is a biotechnology company focused on the development and commercialization of a unique biologic suite of products designed to address unmet and underserved market needs with applications across multiple surgical specialties. We are committed to the development of novel biotechnology and regenerative therapeutics, primarily derived from placental origin. Currently we have filed a US provisional patent application on our core technology, ProLifixTM, an acellular collagen matrix. The Company has over 60 years of experience in biologics manufacturing and comercializaiton, and is led by Chris Broderick who recently launched a neurological tissue transplant technology and was responsible for over $10M in trending global sales.
Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease.
We specialize in human cell culture. Whether you need iPSC-derived cells, disease models, human primary cells or culture media, were here for you.
Medical Tactile is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic`s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic`s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic`s approach to Synthetic Biotics with Ginkgo`s Codebase and Foundry services.